Education and Training
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: inhaled prostacyclin
- drug: inhaled prostacyclin
- drug: prostacyclin
- drug: subcutaneous and intravenous prostacyclin
- drug: oral ERA
- drug: oral PDE5 inhibitors
Eligibility
Inclusion Criteria:
- Clinical diagnosis of PAH, WHO GROUP I
- Prescribed and is currently receiving Tyvaso and/or other FDA-approved therapy for the
treatment of PAH
- Willing and able to provide written informed consent
Exclusion Criteria:
- Previous initiation and permanent discontinuation of Tyvaso
- Participation in an investigational clinical drug or device trial within 30 days of
enrollment
- Current or past diagnosis of lung neoplasm
- Active gastrointestinal or pulmonary bleed at enrollment
- Planned surgical intervention for treatment of PAH e.g., atrial septostomy or
transplant
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Patricia Del Rosario
6507212408
I'm interested